Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2018 Jul;144(7):1339-1346.
doi: 10.1007/s00432-018-2656-y. Epub 2018 May 17.

Tumoral cavitation in colorectal cancer patients with unresectable lung metastasis treated with bevacizumab and chemotherapy

Yu Peng  1   2 , Ye Chen  1 , Xi Zhang  1   2 , Yu Yang  1 , Dan Cao  1 , Feng Bi  1 , Zhipi Li  1 , Hongfeng Gou  3
Affiliations
Review

Tumoral cavitation in colorectal cancer patients with unresectable lung metastasis treated with bevacizumab and chemotherapy

Yu Peng et al. J Cancer Res Clin Oncol. 2018 Jul.

Abstract

Purpose: Efficacy and the frequency of tumor cavitation have not been investigated in patients with metastatic colorectal cancer (mCRC) and lung metastases (LMs) treated with chemotherapy in combination with bevacizumab. This study was aimed to evaluate the efficacy and safety of bevacizumab for unresectable mCRC with LM and to determine the frequency of tumor cavitation, and its correlation with clinical outcomes in patients receiving bevacizumab plus chemotherapy.

Methods: Patients with mCRC and LMs treated with bevacizumab as first- or second-line therapy at West China Hospital, Sichuan University Cancer Center from September 2010 to November 2016 were included in this retrospective study. Data on clinicopathological characteristic were collected and overall survival (OS), progression-free survival (PFS), objective response rate (ORR) and disease control rate (DCR) were determined.

Results: Among 60 patients included in the study, response rate (RR), stable disease (SD), and DCR were 43.6% (17/39), 51.3% (20/39) and 94.9% (37/39) in patients receiving bevacizumab as first-line treatment. Median OS and PFS of the first-line treatment group were 32.4 and 15.5 months, respectively. Among 60, 12 patients (20%) developed cavitation after bevacizumab therapy initiation. Median OS was longer in patients with cavitation than those without cavitation (42.1 vs 30.8 months; p = 0.042) in the first-line treatment group.

Conclusion: Bevacizumab in combination with chemotherapy exhibited promising efficacy in mCRC patients LMs. Moreover, our findings reveal that OS might be affected by new tumor cavitation during antiangiogenic agent treatment.

Keywords: Antiangiogenic agent; Bevacizumab; Cavitation; Colorectal cancer; Lung metastasis.

PubMed Disclaimer

Conflict of interest statement

Author Hongfeng Gou declares that she has no conflict of interest. Author Yu Peng declares that she has no conflict of interest. Author Ye Chen declares that she has no conflict of interest. Author Xi Zhang declares that he has no conflict of interest. Author Yu Yang declares that she has no conflict of interest. Author Dan Cao declares that she has no conflict of interest. Author Feng Bi declares that he has no conflict of interest. Author Zhiping Li declares that he has no conflict of interest.

Figures

Fig. 1
Fig. 1
Overall survival (a) and Progression-free survival (b) of the first-line treatment. Overall survival (c) and Progression-free survival (d) of the second-line treatment
Fig. 2
Fig. 2
Overall survival (a) and progression-free survival (b) were compared between patients who developed cavitation vs those who did not in the first-line treatment
Fig. 3
Fig. 3
Baseline (a) and after therapy (b) CT displaying the onset of cavitation in three patients treated with bevacizumab. The arrow highlights tumor metastases with cavitation
See this image and copyright information in PMC

Similar articles

See all similar articles

Cited by

See all "Cited by" articles

References

    1. Abou-Alfa GK, Schwartz L, Ricci S, Amadori D, Santoro A, Figer A, De Greve J, Douillard J-Y, Lathia C, SchwartzB et al (2006) Phase II study of sorafenib in patients with advanced hepatocellular carcinoma. J Clin Oncol 24:4293–300 - PubMed
    1. Benjamin RS, Choi H, Macapinlac HA, Burgess MA, Patel SR, Chen LL, Podoloff DA, Charnsangavej C (2007) We should desist using RECIST, at least in GIST. J Clin Oncol 25:1760–1764 - PubMed
    1. Chen WQ, Zheng RS, Zhang SW, Zeng HW, Zou XN, HeJ (2017) Analysis of cancer incidence and mortality in China, 2013. Zhong guo Zhong Liu 23:1–10 - PubMed
    1. Choi H, Charnsangavej C, Faria SC, Macapinlac HA, Burgess MA, Patel SR et al (2007) Correlation of computed tomography and positron emission tomography in patients with metastatic gastrointestinal stromal tumor treated at a single institution with imatinib mesylate: proposal of new computed tomography response criteria. J Clin Oncol 25:1753–1759 - PubMed
    1. Crabb SJ, Patsios D, Sauerbrei E, Ellis PM, Arnold A, Goss G et al (2009) Tumor cavitation: impact on objective response evaluation in trials of angiogenesis inhibitors in non-small-cell lung cancer. J Clin Oncol 27:404–410 - PubMed

MeSH terms

LinkOut - more resources